Article
Phase 3 COSMIC-313 Trial Explores Triplet Therapy in Advanced Renal Cell Carcinoma
Rating:
0.0
Views:
68
Likes:
1
Library:
1
The safety and efficacy of cabozantinib plus nivolumab and ipilimumab versus nivolumab/ipilimumab will be evaluated in 676 treatment-naïve patients with advanced or metastatic renal cell carcinoma (RCC) in the phase 3 COSMIC-313 trial.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value